Kurma invests £7.7 million in B cell-selective antibody spin-out from CRT
This article was originally published in Scrip
Executive Summary
Kurma Life Sciences Partners has invested £1.1 million seed financing with the commitment of a further £6.6 million to start-up BliNK Therapeutics, a spin-out company from Cancer Research Technology. BLiNK has a novel antibody platform that is designed to explore the huge spectrum of antibody variability that conventional methods cannot fathom.